HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC).

AbstractBACKGROUND AND AIMS:
Mucin 5AC (MUC5AC) is a glycoprotein found in different epithelial cancers, including biliary tract cancer (BTC). The aims of this study were to investigate the role of MUC5AC as serum marker for BTC and its prognostic value after operation with curative intent.
PATIENTS AND METHOD:
From January 2007 to July 2012, a quantitative assessment of serum MUC5AC was performed with enzyme-linked immunoassay in a total of 88 subjects. Clinical and biochemical data (including CEA and Ca 19-9) of 49 patients with BTC were compared with a control population that included 23 patients with benign biliary disease (BBD) and 16 healthy control subjects (HCS).
RESULTS:
Serum MUC5AC was greater in BTC patients (mean 17.93 ± 10.39 ng/mL) compared with BBD (mean 5.95 ± 5.39 ng/mL; P < .01) and HCS (mean 2.74 ± 1.35 ng/mL) (P < .01). Multivariate analysis showed that MUC5AC was related with the presence of BTC compared with Ca 19-9 and CEA: P < .01, P = .080, and P = .463, respectively. In the BTC group, serum MUC5AC ≥ 14 ng/mL was associated with lymph-node metastasis (P = .050) and American Joint Committee on Cancer and International Union for Cancer Control stage IVb disease (P = .047). Moreover, in patients who underwent operation with curative intent, serum MUC5AC ≥ 14 ng/mL was related to a worse prognosis compared with patients with lesser levels, with 3-year survival rates of 21.5% and 59.3%, respectively (P = .039).
CONCLUSION:
MUC5AC could be proposed as new serum marker for BTC. Moreover, the quantitative assessment of serum MUC5AC could be related to tumor stage and long-term survival in patients with BTC undergoing operation with curative intent.
AuthorsAndrea Ruzzenente, Calogero Iacono, Simone Conci, Francesca Bertuzzo, Gianluca Salvagno, Orazio Ruzzenente, Tommaso Campagnaro, Alessandro Valdegamberi, Silvia Pachera, Fabio Bagante, Alfredo Guglielmi
JournalSurgery (Surgery) Vol. 155 Issue 4 Pg. 633-9 (Apr 2014) ISSN: 1532-7361 [Electronic] United States
PMID24468034 (Publication Type: Journal Article)
CopyrightCopyright © 2014 Mosby, Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • MUC5AC protein, human
  • Mucin 5AC
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biliary Tract Neoplasms (blood, diagnosis, mortality, pathology)
  • Biomarkers, Tumor (blood)
  • Case-Control Studies
  • Cholangiocarcinoma (blood, diagnosis, mortality, pathology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mucin 5AC (blood)
  • Multivariate Analysis
  • Neoplasm Staging
  • Prognosis
  • Prospective Studies
  • Retrospective Studies
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: